



FORM FOR ADVANCE VOTING

Pursuant to the act on temporary exceptions to facilitate meetings in companies and associations the board of Oasmia Pharmaceutical AB (org.nr. 556332–6676) ("Oasmia") has resolved that the shareholders shall be able to exercise their voting rights in advance by mail voting.

Should shareholders want to exercise their voting rights by mail voting this form shall be received by Oasmia no later than on Wednesday 13 May 2020 at 12.00 CET.

Please note that the notice of attendance at the general meeting must be made no later than Friday 8 May 2020 in accordance with the instructions of notice of attendance available in the notice for the general meeting in order for your advance voting shall be valid.

The shareholder below is hereby exercising its voting right for all of the shareholder's shares in Oasmia at the extraordinary general meeting on Thursday 14 May 2020. The voting right is exercised in accordance with the voting options marked below.

.....
(Place) (Date)

.....
(Name of the shareholder)

.....
(Signature) (Clarification of signature)

.....
(Personal identity number/
registration number of shareholder) (Daytime telephone number of shareholder)

For further instructions, see the following page



Instructions for mail voting:

- Complete the shareholder information above.
- Select the preferred voting options below.
- Sign and send the form in the **original** to Oasmia, Oasmia Pharmaceutical AB, Vallongatan 1, 752 28 Uppsala, Sweden, (mark the envelope "Mail voting extraordinary general meeting 14 May 2020").
- If the shareholder is a legal entity, a certificate of registration or corresponding document shall be enclosed with the form. The same applies if the shareholder mail votes by proxy.
- Please note that the notice of attendance at the general meeting must have been given no later than Friday 8 May 2020, even if the shareholder chooses to vote in advance. Instructions regarding this is available in the notice to the general meeting.
- Please note that shareholders who have their shares registered in the name of a nominee must register the shares in the shareholder's own name in order to vote. Instructions regarding this is available in the notice to the general meeting.
- If the shareholder does not wish to exercise its voting rights by advance voting the form for advance voting shall not be submitted.

IMPORTANT INFORMATION:

The shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from electing an option. If the shareholder has provided the form with specific instructions or conditions or if the pre-printed text is amended or supplemented, the vote relating that question may be regarded as invalid. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. If two forms are dated at the same date, the form latest received by the company will be considered. An incomplete or wrongfully completed form, may be discarded without being considered.

The advance voting form, together with any enclosed authorisation documentation, shall be received by Oasmia no later than on Wednesday 13 May 2020 at 12.00 CET. An advance vote can only be withdrawn if the shareholder is present, in person by proxy, at the general meeting.

For complete proposals for the items of the agenda, kindly refer to the notice and proposals on Oasmia's website www.oasmia.com.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's website www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.



Extraordinary general meeting in Oasmia Pharmaceutical AB on 14 May 2020

The options below comprise, unless otherwise stated in the form, the proposals submitted by the board of directors and the nomination committee respectively, which are included in the notice to the extraordinary general meeting.

1. Election of chairman of the general meeting.
Yes <input type="checkbox"/> No <input type="checkbox"/>
2. Approval of the agenda.
Yes <input type="checkbox"/> No <input type="checkbox"/>
5. Determination of whether the general meeting has been duly convened.
Yes <input type="checkbox"/> No <input type="checkbox"/>
6. Resolution regarding new number of board members.
Yes <input type="checkbox"/> No <input type="checkbox"/>
7. The nomination committee's proposal regarding board of directors and chairman of the board: Anders Härfstrand (re-election, new chairman), Sven Rohmann (re-election), Peter Zonabend (re-election), Hege Hellström (re-election), Birgit Stattin Norinder (new election).
Yes <input type="checkbox"/> No <input type="checkbox"/>
8. Resolution regarding remuneration to the members of the board.
Yes <input type="checkbox"/> No <input type="checkbox"/>
9. Approval of employee stock options to CEO François Martelet.
Yes <input type="checkbox"/> No <input type="checkbox"/>